The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2026 | Updates in systemic therapies for HER2+ gastroesophageal adenocarcinoma
Filippo Pietrantonio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses updates in systemic therapy for patients with HER2-positive gastroesophageal adenocarcinoma, highlighting the emergence of novel monoclonal antibodies such as zanidatamab, which has replaced trastuzumab in combination with chemotherapy and a PD-1 inhibitor. Dr Pietrantonio notes that the combination of zanidatamab, a PD-1 inhibitor, and chemotherapy is the preferred option for patients with HER2-positive disease, offering a higher magnitude of benefit, and that sequential HER2-targeting is now standard of care, with options like trastuzumab deruxtecan available in the second line. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
